WO2018170724A1 - 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 - Google Patents

2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 Download PDF

Info

Publication number
WO2018170724A1
WO2018170724A1 PCT/CN2017/077459 CN2017077459W WO2018170724A1 WO 2018170724 A1 WO2018170724 A1 WO 2018170724A1 CN 2017077459 W CN2017077459 W CN 2017077459W WO 2018170724 A1 WO2018170724 A1 WO 2018170724A1
Authority
WO
WIPO (PCT)
Prior art keywords
eutectic
monohydrate
crystal form
fumaric acid
pyrazole
Prior art date
Application number
PCT/CN2017/077459
Other languages
English (en)
French (fr)
Inventor
盛晓红
盛晓霞
汪晶
Original Assignee
杭州领业医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州领业医药科技有限公司 filed Critical 杭州领业医药科技有限公司
Priority to CN201780090404.6A priority Critical patent/CN110582279B/zh
Priority to US16/496,023 priority patent/US10995083B2/en
Priority to PCT/CN2017/077459 priority patent/WO2018170724A1/zh
Publication of WO2018170724A1 publication Critical patent/WO2018170724A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application relates to the field of medicinal chemical crystallization technology.
  • the present application relates to 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrole And eutectic of [1,2-b]pyrazole and succinic acid, 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]- a eutectic of 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole with fumaric acid, and also relates to the crystalline form of the eutectic, a process for the preparation thereof, a pharmaceutical composition thereof and use thereof.
  • the types of solid forms of drugs are mainly polymorphs, salts, hydrates or solvates and eutectic.
  • the drug eutectic is usually a crystal in which an active pharmaceutical ingredient (API) and a cocrystal former (CCF) are combined by a weak interaction force at a fixed stoichiometric ratio.
  • the pharmaceutically active ingredient herein may be a free active ingredient or a salt-forming active ingredient.
  • Weak interactions are defined as interactions that are neither ionic nor covalent, including, for example, hydrogen bonds, van der Waals forces, ⁇ - ⁇ interactions, and halogen bonds.
  • a eutectic is a multi-component crystal that includes both a binary eutectic formed between two neutral solids and a multi-element eutectic.
  • the eutectic itself may also exhibit a polymorphic form, or it may be a hydrate or a solvate. It has been reported that the formation of eutectic has the opportunity to improve the crystallization and physical and chemical properties of the drug.
  • TGF- ⁇ transforming growth factor beta
  • TGF- ⁇ includes three subtypes of TGF- ⁇ 1, TGF- ⁇ 2, and TGF- ⁇ 3, which can affect the growth, differentiation, and gene expression of various cell types. TGF- ⁇ is closely related to many diseases. LY2157299 is a TGF- ⁇ signal transduction inhibitor that can be used to treat cancer, precancerous lesions, nephropathy, fibrosis and ocular diseases caused by abnormal TGF- ⁇ activity.
  • the patent document CN100345852C reports the preparation method of LY2157299 and discloses mass spectrometry data
  • the patent document US7872020B2 reports the preparation method of LY2157299 monohydrate and discloses nuclear magnetic resonance spectrum, mass spectrometry and XRPD detection data.
  • the present inventors have found that LY2157299 monohydrate obtained according to the preparation method of US7872020B2 has disadvantages such as poor solubility and unstable crystal form at high temperature.
  • the object of the present invention is to provide 2-(6-methyl-pyridin-2-yl)-3yl-[6-amido-quinolin-4-yl]-5,6-di Co-crystals of hydrogen-4H-pyrrolo[1,2-b]pyrazole and their crystal forms and preparation methods, pharmaceutical compositions and uses comprising the same.
  • the eutectic is a stable crystalline solid and should have one or more improved properties, particularly in terms of crystallinity, solubility, hygroscopicity, morphology, formulation processability, crystal form stability, and the like.
  • the present invention relates to a method for producing the eutectic, a method for preparing a eutectic single crystal, the eutectic pharmaceutical composition, and uses thereof.
  • one of the contents of the present invention is to provide 2-(6-methyl-pyridin-2-yl)-3yl-[6-amido-quinolin-4-yl]-5,6-di
  • a succinic acid eutectic of hydrogen-4H-pyrrolo[1,2-b]pyrazole (abbreviated as succinic acid eutectic) and its crystal form (abbreviated as "succinic acid eutectic crystal form") and a preparation method thereof.
  • the succinic acid cocrystal comprising 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H- Pyrrolo[1,2-b]pyrazole and succinic acid, and 2-(6-methyl-pyridin-2-yl)-3yl-[6-amido-quinolin-4-yl]-5,
  • the molar ratio of 6-dihydro-4H-pyrrolo[1,2-b]pyrazole to succinic acid was 1:0.5.
  • the succinic acid eutectic is a hydrate containing 1 mole of water.
  • the X-ray powder diffraction pattern of the succinic acid eutectic crystal form has a 2 ⁇ value of 10.8° ⁇ 0.2°, 11.6° ⁇ 0.2°, 15.5° ⁇ 0.2°, and 20.2° ⁇ 0.2°. Characteristic peaks.
  • the succinic acid eutectic crystal form uses Cu-K ⁇ radiation, and its X-ray powder diffraction pattern is also at 2 ⁇ values of 12.3° ⁇ 0.2°, 16.8° ⁇ 0.2°, 18.0°.
  • the succinic acid eutectic crystal form uses Cu-K ⁇ radiation, and the X-ray powder diffraction pattern thereof is also at a 2 ⁇ value of 12.3° ⁇ 0.2°, 16.8° ⁇ 0.2°, 18.0.
  • the eutectic type FTIR spectra 3473cm -1 ⁇ 2cm -1, 3141cm -1 ⁇ 2cm -1 in wave number, 1693cm -1 ⁇ 2cm -1, 1580cm -1 ⁇ 2cm -1 , 1429cm -1 ⁇ 2cm -1 , 1322cm -1 ⁇ 2cm -1 , 1189cm -1 ⁇ 2cm -1 , 864cm -1 ⁇ 2cm -1 , 831cm -1 ⁇ 2cm -1 , 806cm - 1 ⁇ 2cm -1 and at 609cm -1 ⁇ 2cm -1 with characteristic peaks.
  • Another object of the present invention is to provide a succinic acid eutectic single crystal and a process for the preparation thereof.
  • the single crystal of the succinic eutectic crystal form has the following atomic coordinates.
  • a single crystal of the eutectic eutectic crystal form is prepared.
  • the specific operation of the preparation is as follows: a succinic acid eutectic methanol solution is volatilized at room temperature to obtain a single crystal.
  • the "pore volatilization" is a process in which a container containing a solution is volatilized and crystallized at a corresponding temperature through a single orifice having a diameter of 2 mm.
  • the succinic acid eutectic crystal form of the present invention has the following beneficial properties as compared to the prior art LY2157299 monohydrate:
  • the crystal morphology of the succinic acid eutectic crystal form of the present invention is a regular bulk crystal having better fluidity and workability than the fine needle-like LY2157299 monohydrate.
  • the succinic acid eutectic crystal form of the present invention is allowed to stand under the condition of 25 ° C - 60% relative humidity for 6 months, the crystal form is unchanged, and the stability is good.
  • the succinic acid eutectic crystal form of the present invention has a plurality of advantageous properties compared to the prior art monohydrate of LY2157299, and is more suitable as a solid form of the active ingredient in a pharmaceutical preparation.
  • the prior art LY2157299 has a low solubility of the monohydrate, which affects the absorption and utilization of the preparation.
  • the succinic acid eutectic crystal form of the invention has high solubility in water, and has higher dissolution rate and bioavailability.
  • the succinic acid eutectic crystal form has good stability, and can better ensure the quality, safety and stability of the pharmaceutically active ingredient itself and the formulation form containing the succinic acid eutectic crystal form during manufacture and storage.
  • the invention provides a method for preparing a eutectic eutectic crystal form, comprising any one of the following methods:
  • the solvent is selected from the group consisting of methanol, acetonitrile or water;
  • the molar ratio of the LY2157299 monohydrate to succinic acid is 1:0.5 to 1:1.2, more preferably 1:0.5 to 1:0.6;
  • the mass to volume ratio of the LY2157299 monohydrate to the solvent is 80 mg: 1 mL to 200 mg: 1 mL, more preferably 80 mg: 1 mL to 150 mg: 1 mL;
  • the polishing temperature is 10 to 40 ° C, and more preferably 10 to 30 ° C.
  • the solvent is selected from C 1 - C 4 alcohol, ethyl acetate or acetone;
  • the solvent is methanol
  • the molar ratio of the LY2157299 monohydrate to succinic acid is 1:0.5 to 1:1.2, more preferably 1:1.0 to 1:1.2;
  • the mass ratio of the LY2157299 monohydrate to the solvent is 50 to 100 mg/mL;
  • the temperature of the stirring and crystallization is 10 to 40 ° C, more preferably 10 to 30 ° C;
  • the stirring and crystallization is carried out for 4 to 16 hours.
  • a second aspect of the present invention provides 2-(6-methyl-pyridin-2-yl)-3yl-[6-amido-quinolin-4-yl]-5,6-di Eutectic of hydrogen-4H-pyrrolo[1,2-b]pyrazole and fumaric acid (referred to as fumaric acid eutectic) and its crystal form (referred to as "fumaric acid eutectic crystal form”) and preparation method thereof .
  • the X-ray powder diffraction pattern of the fumaric acid eutectic crystal form has characteristic peaks at 2 ⁇ values of 8.3 ° ⁇ 0.2 °, 9.8 ° ⁇ 0.2 °, and 16.7 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of the fumaric acid eutectic crystal form is also at a 2 ⁇ value of 15.5 ° ⁇ 0.2 °, 16.4 ° ⁇ 0.2 °, 23.4 ° ⁇ 0.2 °, 23.7. There are characteristic peaks at one or more of ° ⁇ 0.2°, 24.2° ⁇ 0.2°, 27.1° ⁇ 0.2°, and 28.3° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the fumaric acid eutectic crystal form is also at a 2 ⁇ value of 15.5 ° ⁇ 0.2 °, 16.4 ° ⁇ 0.2 °, 23.4 ° ⁇ 0.2 °, There are characteristic peaks at 23.7 ° ⁇ 0.2 °, 24.2 ° ⁇ 0.2 °, 27.1 ° ⁇ 0.2 ° and 28.3 ° ⁇ 0.2 °.
  • fumaric acid eutectic crystal form has an XRPD pattern as shown in FIG.
  • the fumaric FTIR eutectic type is 3350cm -1 ⁇ 2cm -1, 3153cm -1 ⁇ 2cm -1 in wave number, 1681cm ⁇ 2cm -1 -1 , 1588cm -1 ⁇ 2cm -1 , 1395cm -1 ⁇ 2cm -1 , 1320cm -1 ⁇ 2cm -1 , 1149cm -1 ⁇ 2cm -1 , 971cm -1 ⁇ 2cm -1 , 870cm -1 ⁇ 2cm -1 , 835cm -1 ⁇ 2cm -1, at 747cm -1 ⁇ 2cm -1, and 634cm -1 ⁇ 2cm -1 with characteristic peaks.
  • Another object of the present invention is to provide a fumaric acid eutectic single crystal and a process for the preparation thereof.
  • the single crystal of the fumaric acid eutectic crystal form has the following atomic coordinates.
  • the single crystal of the fumaric acid eutectic crystal form is prepared.
  • the specific operation of the preparation is, for example, volatilization of a fumaric acid eutectic methanol solution at room temperature to obtain a single crystal.
  • the "pore volatilization" is a process in which a container containing a solution is volatilized and crystallized at a corresponding temperature through a single orifice having a diameter of 2 mm.
  • the fumaric acid eutectic crystal form of the present invention has the following beneficial properties as compared to the prior art LY2157299 monohydrate:
  • the crystal form of the fumaric acid eutectic crystal form of the present invention is a regular bulk crystal having better fluidity and process processability than the fine needle-like LY2157299 monohydrate.
  • the fumaric acid eutectic crystal form of the present invention is allowed to stand under the condition of 25 ° C - 60% relative humidity for 6 months, the crystal form is unchanged, and the stability is good.
  • the above beneficial properties indicate that the fumaric acid eutectic crystal form of the present invention has a plurality of advantageous properties as compared with the prior art monohydrate of LY2157299, and is more suitable as a solid form of the active ingredient in a pharmaceutical preparation.
  • the prior art LY2157299 has a low solubility of the monohydrate, which affects the absorption and utilization of the preparation.
  • the fumaric acid eutectic crystal form of the present invention has high solubility in water, and has higher dissolution rate and bioavailability.
  • the fumaric acid eutectic crystal form of the invention has good stability, and can better ensure the quality, safety and stability of the pharmaceutically active ingredient itself and the preparation form containing the fumaric acid eutectic crystal form during manufacture and storage. .
  • the invention provides a preparation method of a fumaric acid eutectic crystal form, which comprises any one of the following methods:
  • the mass to volume ratio of the mixture and the solvent is 60 mg: 1 mL to 160 mg: 1 mL;
  • the molar ratio of the LY2157299 monohydrate to fumaric acid is 1:0.5 to 1:1.2, more preferably 1:0.5 to 1:0.6;
  • the polishing temperature is 10 to 40 ° C, and more preferably 10 to 30 ° C.
  • the solvent is selected from C 1 to C 4 alcohol, ethyl acetate or acetone;
  • the solvent is methanol
  • the molar ratio of the LY2157299 monohydrate to fumaric acid is 1:0.5 to 1:1.2, more preferably 1:1.0 to 1:1.2;
  • the mass ratio of the LY2157299 monohydrate to the solvent is 50 to 100 mg/mL;
  • the temperature of the stirring and crystallization is 10 to 40 ° C, more preferably 10 to 30 ° C;
  • the stirring and crystallization is carried out for 4 to 16 hours.
  • the raw material "LY2157299” may be the disclosed LY2157299 compound, its crystal form or its amorphous form, and includes, for example, but not limited to, LY2157299 monohydrate obtained by the preparation method of the patent document US7872020B2. . These patent documents are incorporated herein by reference in their entirety.
  • the "C 1 -C 4 alcohol” includes methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, and tert-butanol.
  • the "room temperature” means 10 to 30 °C.
  • the “stirring” can be carried out by conventional methods in the art, such as stirring, including magnetic stirring, Mechanical stirring, the stirring speed is 50 to 1800 rpm, preferably 300 to 900 rpm.
  • the "grinding” can be carried out by a conventional method in the art, that is, grinding the sample in a mortar.
  • the "separation" can be carried out by conventional methods in the art, such as centrifugation or filtration.
  • the filtration under reduced pressure is generally carried out by suction filtration at a pressure of less than atmospheric pressure at room temperature, preferably at a pressure of less than 0.09 MPa.
  • the "drying" can be accomplished using conventional techniques in the art, such as drying at ambient temperature, blast drying or reduced pressure drying.
  • the drying apparatus and method are not limited and may be a fume hood, a blast oven, a spray dryer, a fluidized bed drying or a vacuum oven; the pressure may be reduced or normal pressure, preferably the pressure is less than 0.09 MPa.
  • the drying temperature is 10 to 40 ° C, and the drying time is 10 to 72 hours, preferably 2 to 24 hours, more preferably 2 to 8 hours.
  • crystalline means that the compound is characterized by the X-ray powder diffraction pattern indicated, having a unique ordered molecular arrangement or configuration within the crystal lattice. It is well known to those skilled in the art that the experimental error therein depends on instrument conditions, sample preparation, and sample purity.
  • the 2 ⁇ angle of the peaks in the XRPD pattern will typically vary slightly from instrument to sample. The difference in peak angle may vary by 1°, 0.8°, 0.5°, 0.3°, 0.1°, etc. depending on the instrument, and the sample may be ⁇ 0.2°.
  • the relative intensity of the peaks may vary with sample, sample preparation, and other experimental conditions, so the order of peak intensities cannot be the sole or decisive factor.
  • any crystal form having the same or similar characteristic peaks as the X-ray powder diffraction pattern of the present invention is within the scope of the present invention even if the peak intensity and relative intensity are different.
  • Single crystal form means a single crystal form as detected by X-ray powder diffraction.
  • the eutectic of the present invention is pure, singular, and substantially free of any other crystalline or amorphous state.
  • substantially free in the context of the invention, when used to refer to a new crystalline form, means that the new crystalline form comprises at least 80% by weight of the compound present, more preferably at least 90% by weight, especially at least 95% by weight. ), especially at least 99% by weight.
  • the present invention provides a pharmaceutical composition for use in the preparation of a disease for treating or preventing TGF- ⁇ ;
  • the disease associated with TGF- ⁇ includes cancer, cancer Pre-lesion, kidney disease, fibrosis and eye diseases.
  • the pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of a pharmaceutically active ingredient selected from the group consisting of a LY2157299 co-crystal of the invention or a pharmaceutically acceptable salt of LY2157299, and at least one pharmaceutically acceptable carrier or adjuvant, wherein the pharmaceutical composition comprises
  • inventive LY2157299 eutectic includes a eutectic formed by LY2157299 with succinic acid and a eutectic formed by LY2157299 and fumaric acid.
  • the pharmaceutical composition may also comprise one or more additional pharmaceutically active ingredients, such as other TGF-[beta] antagonists, anti-proliferative/anti-tumor drugs.
  • a method of treating a human patient comprises administering a TGF-[beta] antagonist.
  • the TGF- ⁇ antagonist is prepared in the form of a pharmaceutical preparation which can be administered by oral and rectal route, topical, subcutaneous or parenteral routes such as injection, including tablets, powders, capsules, troches, emulsions, creams, syrups , sublingual tablets, small medicine bags, cachets, tinctures, gels, suspensions, injection solutions, aerosols, ointments, suppositories, and a combination of the above forms.
  • the LY2157299 co-crystals and compositions of the present invention may be active in a single dose or in divided doses.
  • the dosage is administered to the patient within the dosage range of 0.5 mg/kg to 50 mg/kg.
  • a single dose may contain from about 0.5 mg to about 1000 mg of the active ingredient of the compound.
  • the composition may contain from about 0.5 to about 500 mg of the active ingredient, especially 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 80 mg/100 mg, 120 mg, 150 mg, 175 mg.
  • the active ingredient is administered in a daily dose of from 0.5 mg/kg to 40 mg/kg of the active ingredient.
  • the amount of the compound actually administered should be determined according to various circumstances, including the severity of the condition being treated, the age of the patient, the physical condition, the sex, the activity and metabolism of the administered compound, the route of administration, and thus the preferred dosage range described above is absent. The meaning limits the scope of the invention in any way.
  • the compound may be co-crystallized with at least one compound as specified herein, mixed with a pharmaceutically acceptable carrier, excipient, adjuvant, or in the form of a capsule, sachet, sachet, paper or other outer shell or stent.
  • a pharmaceutically acceptable carrier such as an ampoule
  • the carrier, excipient, adjuvant may be a solid, semi-solid or liquid material.
  • Carriers, excipients, and adjuvants which can be used in the pharmaceutical composition of the present invention are, for example, starch, sugar, syrup, sorbitol, mannitol, glycol, paraffin, kaolin, calcium silicate, silica, polyethylene. Pyrrolidone, calcium phosphate, cocoa butter, esters, oils, alginates, gums, methylcellulose, microcrystalline cellulose, lubricants, binders, disintegrants, and the like.
  • Preferred pharmaceutical forms of the invention are tablets, powders, capsules, injections (solutions), creams, ointments and aerosols.
  • Figure 1 is an XRPD pattern of the LY2157299 monohydrate crystal form prepared according to US7872020B2
  • Figure 2 shows the DSC pattern of the LY2157299 monohydrate crystal form prepared by US7872020B2
  • Figure 3 is a TGA map of the LY2157299 monohydrate form prepared by reference to US7872020B2
  • Figure 4 shows the PLM pattern of the LY2157299 monohydrate crystal form prepared according to US7872020B2
  • Figure 6 is a DSC pattern of the succinic acid eutectic crystal form of the present invention
  • Figure 7 is a TGA map of the eutectic eutectic crystal form of the present invention
  • Figure 8 is a PLM map of a single crystal of a succinic eutectic crystal form of the present invention.
  • Figure 9 is a schematic view showing the molecular structure of a single crystal of a eutectic eutectic crystal form of the present invention
  • Figure 10 is an IR spectrum of the eutectic eutectic crystal form of the present invention
  • Figure 11 is a comparison of the XRPD of the measured (lower) and single crystal diffraction simulation (top) of the succinic acid eutectic crystal form of the present invention.
  • Figure 12 is an XRPD pattern of the fumaric acid eutectic crystal form of the present invention.
  • Figure 13 is a DSC pattern of the fumaric acid eutectic crystal form of the present invention
  • Figure 15 is a PLM map of a single crystal of a fumaric acid eutectic crystal of the present invention.
  • Figure 16 is a schematic view showing the molecular structure of a single crystal of a fumaric acid eutectic crystal form of the present invention
  • Figure 17 is an IR spectrum of the fumaric acid eutectic crystal form of the present invention.
  • Figure 18 is a comparison of the XRPD of the measured (lower) and single crystal diffraction simulations of the fumaric acid eutectic crystal form of the present invention.
  • X-ray powder diffraction (XRPD): The instrument was a Bruker D8 Advance diffractometer. The samples were tested at room temperature. The detection conditions are as follows, the angle range is 3 to 40 ° 2 ⁇ , the step size is 0.02 ° 2 ⁇ , and the speed is 0.2 second / step.
  • the instrument is Bruker SMART APEX II
  • the detector is 4K CCD
  • the detection conditions are: ambient temperature 296K
  • enhanced Mo light source wavelength
  • the data analysis software is Bruker SHELXTL.
  • Differential thermal analysis data was taken from the TA Instruments Q200 MDSC.
  • the detection method is as follows: 1 to 10 mg of the sample is placed in a closed-cell aluminum crucible, and the sample is raised from room temperature to 300 ° C under the protection of 40 mL/min dry N 2 at a heating rate of 10 ° C/min.
  • Thermogravimetric analysis data was taken from the TA Instruments Q500 TGA.
  • the detection method is as follows: 5 to 15 mg of the sample is placed in a platinum crucible, and the sample is raised from room temperature to a temperature of 10 ° C/min under the protection of 40 mL/min dry N 2 by means of segmented high-resolution detection. 350 ° C.
  • Nuclear magnetic resonance spectroscopy data ( 1 H NMR) were taken from a Bruker Avance II DMX 400 MHZ NMR spectrometer. A sample of 1 to 5 mg was weighed and dissolved in a nuclear magnetic sample tube with about 0.5 mL of deuterated reagent for detection.
  • the polarized light microscope (PLM) model is XR-500E, the eyepiece magnification is 10 times, and the objective lens magnification is 10 times. A small amount of the sample was taken on a glass slide, and 1 drop of silicone oil was dropped, and the cover glass was covered and dispersed for observation.
  • IR Infrared spectroscopy
  • LY2157299 monohydrate was prepared by the method of Example 1 in the patent document US7872020B2.
  • the TGA spectrum is shown in Figure 3: the step weight loss is 4.7% at 80-120 ° C, about one mole of water, and the decomposition temperature is about 323 ° C;
  • the PLM spectrum is shown in Figure 4 and is shown as a needle-like fine crystal.
  • the XRPD pattern is shown in Fig. 5 and is shown as a crystalline substance; the XRPD diffraction peak, the interplanar spacing and the diffraction peak intensity data are shown in Table 1.
  • the TGA spectrum is shown in Figure 7, and the dehydration temperature is about 80 °C.
  • Example 1 An appropriate amount of the succinic acid eutectic in Example 1 was formed into a solution in methanol, and the pores were volatilized at room temperature to obtain a single crystal of a succinic acid eutectic crystal form.
  • a, b, and c represent the unit cell axis length, ⁇ , ⁇ , and ⁇ represent dihedral angles, and Z represents LY2157299 ⁇ H 2 O ⁇ 0.5HOOC(CH 2 ) 2 COOH as a unit molecule in each unit cell.
  • the number, V represents the unit cell volume, and D calc represents the cell density.
  • the single crystal PLM spectrum is shown in Fig. 8 and is shown as a bulk crystal.
  • the molecular structure of the single crystal unit cell is shown in Figure 9. It shows that the LY2157299 molecule and water molecules are in the unit cell, and the succinic acid molecule is at the apex of the unit cell.
  • the eutectic molecule consists of a LY2157299 molecule, a water molecule and a half succinic acid. Molecular composition.
  • the comparison chart shown in Fig. 11 is a single crystal simulated XRPD pattern (top) and a measured XRPD pattern (bottom), showing that the two are substantially identical.
  • the samples prepared in Examples 3 to 11 had the same or similar XRPD pattern, DSC pattern (not shown) and TGA pattern (not shown), and IR pattern (not shown) as the sample of Example 1.
  • the samples of Examples 3 to 11 are identical to the samples of Example 1 in the same eutectic.
  • the XRPD pattern thereof is shown in Fig. 12 and is shown as a crystalline substance; the XRPD diffraction peak, the interplanar spacing, and the diffraction peak intensity data are shown in Table 4.
  • Table 4 Diffraction peak angle, interplanar spacing and peak relative intensity data of fumaric acid eutectic
  • Example 12 An appropriate amount of the fumaric acid eutectic of Example 12 was formed into a solution in methanol, and the pores were volatilized at room temperature to obtain a single crystal of the fumaric acid eutectic crystal form.
  • a, b, and c represent the unit cell axis length, ⁇ , ⁇ , and ⁇ represent dihedral angles, and Z represents the number of molecules in each unit cell with LY2157299 ⁇ 0.5HOOC(CH) 2 COOH, and V represents The unit cell volume, Dcalc represents the cell density.
  • the single crystal PLM spectrum is shown in Fig. 15, and is shown as a bulk crystal.
  • the single crystal unit cell spectrum is shown in Fig. 16. It shows that the LY2157299 molecule is in the unit cell, the fumaric acid molecule is on the surface, and the eutectic molecule is composed of one LY2157299 molecule and half a fumaric acid molecule.
  • the comparison chart shown in Fig. 18 is an XRPD pattern (top) and a measured XRPD pattern (bottom) of the fumaric acid single crystal simulation, showing that the two are substantially identical.
  • the samples prepared in Examples 14 to 22 had the same or similar XRPD patterns (not shown), DSC patterns (not shown), TGA patterns (not shown), and IR patterns (not shown) as the samples of Example 12.
  • the samples of Examples 14-22 were identical to the samples of Example 12 in the same eutectic.
  • succinic eutectic crystal form or fumaric acid eutectic crystal form, starch, microcrystalline cellulose, silica and talc are mixed and filled into capsules.
  • the eutectic eutectic crystal form or fumaric acid eutectic crystal form, starch and microcrystalline cellulose are passed through a 20 mesh screen and thoroughly mixed.
  • the hydroxypropyl methylcellulose solution was mixed with the resulting powder, and then passed through a 16 mesh sieve, and the obtained granules were dried and passed through a 16 mesh sieve.
  • sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a 30 mesh sieve, were added to the granules, and after mixing, they were compressed on a tablet machine to give tablets each weighing 150 mg.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及式(I)所示的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑(Galunisertib或LY2157299)与共晶形成物形成的共晶，与Galunisertib已知的固体形式相比，本发明的共晶在稳定性、溶解度等方面具有优势。本发明还涉及所述共晶的晶型及其制备方法，其药物组合物及其在制备用于预防和/或治疗与TGF-β有关的疾病中的用途。

Description

2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 技术领域
本申请涉及药物化学结晶技术领域。具体而言，本申请涉及2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与琥珀酸的共晶，2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与富马酸的共晶，还涉及所述共晶的晶型及其制备方法、其药物组合物和用途。
背景技术
药物固体形态的种类主要有多晶型、盐、水合物或溶剂化物以及共晶。药物共晶通常是药物活性成分(active pharmaceutical ingredient,API)与共晶前体(cocrystal former,CCF)以固定的化学计量比通过弱相互作用力结合而成的晶体。这里的药物活性成分可以是游离态的活性成分，也可以泛指成盐的活性成分。弱相互作用被定义为既不是离子键也不是共价键的相互作用，例如包括氢键、范德华力、π-π相互作用和卤键。共晶是一种多组分晶体，既包括两种中性固体之间形成的二元共晶，也包括多元共晶。共晶本身亦可以呈现多晶型，也可以是水合物或溶剂化物。有报道认为形成共晶可以有机会改善药物的结晶性质和理化性能。
2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑，又名LY2157299，是一种转化生长因子β(TGF-β)信号转导抑制剂，英文名为Galunisertib，其化学结构式如下式(I)所示:
Figure PCTCN2017077459-appb-000001
TGF-β包括三种亚型TGF-β1、TGF-β2、TGF-β3可影响多种细胞类型的生长、分化和基因表达。TGF-β与许多疾病有密切关系。LY2157299作为TGF-β信号转导抑制剂，可用于治疗由TGF-β活性异常导致的癌症、癌前病变、肾病、纤维变性及眼部疾病等。
专利文献CN100345852C报道了LY2157299的制备方法并公开了质谱数据；专利文献US7872020B2报道了LY2157299一水合物的制备方法并公开了核磁氢谱、质谱、XRPD检测数据。本发明人研究发现，按照US7872020B2制备方法得到的LY2157299一水合物，其具有溶解度差及高温下晶型不稳定等缺点。
鉴于现有技术尚存不足，本领域仍需要开发具有更多改进性能的结晶态的LY2157299，包括共晶，以满足药物制剂对于活性成分溶解度、稳定性、形貌等物化性质的严格要求。
发明内容
针对现有技术的不足，本发明的目的是提供2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶以及它们的晶型和制备方法、包含所述共晶的药物组合物和用途。所述共晶为稳定的结晶态固体，应具有一种或多种改进的特性，特别在结晶度、溶解度、吸湿性、形貌、制剂可加工性、晶型稳定性等方面。此外，本发明还涉及所述共晶的制备方法、共晶单晶的制备方法、所述共晶的药物组合物及其用途。
根据本发明目的，本发明的内容之一是提供2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的琥珀酸共晶(简称琥珀酸共晶)及其晶型(简称“琥珀酸共晶晶型”)及其制备方法。
所述的琥珀酸共晶，含有2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸，且2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸的摩尔比为1:0.5。
所述琥珀酸共晶为水合物，含1摩尔水。
使用Cu-Kα辐射，所述琥珀酸共晶晶型的X-射线粉末衍射图在2θ值为10.8°±0.2°、11.6°±0.2°、15.5°±0.2°和20.2°±0.2°处具有特征峰。
在本发明优选的一个实施方案中，所述琥珀酸共晶晶型使用Cu-Kα辐射，其X-射线粉末衍射图还在2θ值为12.3°±0.2°、16.8°±0.2°、18.0°±0.2°、21.3°±0.2°、21.7°±0.2°、22.0°±0.2°、24.6°±0.2°和25.2°±0.2°的一处或多处具有特征峰。在本发明又一个优选的实施方案中，所述琥珀酸共晶晶型使用Cu-Kα辐射，其X-射线粉末衍射图还在2θ值为12.3°±0.2°、16.8°±0.2°、18.0°±0.2°、21.3°±0.2°、21.7°±0.2°、22.0°±0.2°、24.6°±0.2°和25.2°±0.2°处具有特征峰。非限制性地，所述琥珀酸共的晶型的一个具体实例具有如图5所示的XRPD图谱。
在本发明另一个优选的实施方案中，所述共晶晶型的傅里叶红外光谱在波数为3473cm-1±2cm-1、3141cm-1±2cm-1、1693cm-1±2cm-1、1580cm-1±2cm-1、1429cm-1±2cm-1、1322cm-1±2cm-1、1189cm-1±2cm-1、864cm-1±2cm-1、831cm-1±2cm-1、806cm-1±2cm-1和609cm-1±2cm-1处具有特征峰。
本发明的另一个目的是提供琥珀酸共晶单晶及其制备方法。
所述琥珀酸共晶晶型的单晶，为三斜晶系，空间群P1，在296K条件下进行测量，具有以下的单晶晶胞参数：
Figure PCTCN2017077459-appb-000002
α＝87.3°±0.2°；β＝78.1°±0.2°；γ＝89.2°±0.2°。
优选地，该共晶单晶的晶胞参数为
Figure PCTCN2017077459-appb-000003
Figure PCTCN2017077459-appb-000004
α＝87.3°～78.4°；β＝78.1°～78.2°；γ＝89.2°～89.3°。更具体地， 该共晶单晶的晶胞参数为
Figure PCTCN2017077459-appb-000005
α＝87.33°～78.34°；β＝78.12°～78.13°；γ＝89.21°～89.23°。
在一个具体的实施方案中，晶胞参数为
Figure PCTCN2017077459-appb-000006
Figure PCTCN2017077459-appb-000007
α＝87.337(9)°；β＝78.123(10)°；γ＝89.220(10)°。
进一步地，在本发明的一个具体实施方案中，所述的琥珀酸共晶晶型的单晶具有以下的原子坐标。
Figure PCTCN2017077459-appb-000008
在本发明优选的一个实施方案中，制备得到所述琥珀酸共晶晶型的单晶。制备的具体操作例如：将琥珀酸共晶的甲醇溶液进行室温小孔挥发，得到单晶。所述“小孔挥发”是将装有溶液的容器在相应温度下通过直径为2毫米的单个小孔进行挥发结晶。
与现有技术的LY2157299一水合物相比，本发明的琥珀酸共晶晶型具有以下有益性质：
(1)由对比例1可知，已知的LY2157299一水合物在室温下水中的表观溶解度小于50μg/mL，而本发明琥珀酸共晶晶型在水中的表观溶解度为130μg/mL，因此本发明的琥珀酸共晶晶型有更好的水中表观溶解度。
(2)本发明的琥珀酸共晶晶型的晶体形貌为规则块状晶体，与细针状LY2157299一水合物相比，具有更好的流动性和可加工性。
(3)本发明的琥珀酸共晶晶型在25℃-60％相对湿度条件下放置6个月，晶型不变，稳定性好。
以上有益性质表明：与现有技术的LY2157299的一水合物相比，本发明的琥珀酸共晶晶型具有多种优势性能，更适合作为药物制剂中活性成分的固体形态。现有技术的LY2157299的一水合物溶解度低，影响制剂的吸收、利用。而本发明琥珀酸共晶晶型水中溶解度高，具有更高的溶出度和生物利用度。且琥珀酸共晶晶型稳定性好，能更好地保证药物活性成分自身和含有琥珀酸共晶晶型的制剂剂型在制造和存储等过程中质量、安全性和稳定性。
本发明提供琥珀酸共晶晶型的制备方法，包括下述方法中的任意一种：
(1)将溶剂加入到LY2157299一水合物和琥珀酸的混合物中，研磨至干，得到所述的琥珀酸共晶晶型；所述溶剂选自甲醇、乙腈或水；
优选地，所述LY2157299一水合物与琥珀酸的摩尔比为1:0.5～1:1.2，更优选为1:0.5～1:0.6；
优选地，所述LY2157299一水合物与溶剂的质量体积比为80mg:1mL～200mg:1mL，更优选为80mg:1mL～150mg:1mL；
优选地，所述研磨的温度为10～40℃，更优选为10～30℃。
(2)将LY2157299一水合物和琥珀酸的混合物在溶剂中形成混悬液，搅拌析晶，进而分离晶体、干燥，得到所述的琥珀酸共晶晶型；所述溶剂选自C1～C4醇、乙酸乙酯或丙酮；
优选地，所述溶剂为甲醇；
优选地，所述LY2157299一水合物和琥珀酸的摩尔比为1:0.5～1:1.2，更优选为1:1.0～1:1.2；
优选地，所述LY2157299一水合物与溶剂的质量体积比为50～100mg/mL；
优选地，所述搅拌析晶的温度为10～40℃，更优选为10～30℃；
优选地，所述搅拌析晶的时间为4～16小时。
根据本发明目的，本发明的内容之二是提供2-(6-甲基-吡啶-2-基)-3基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与富马酸的共晶(简称富马酸共晶)及其晶型(简称“富马酸共晶晶型”)及其制备方法。
所述的富马酸共晶，其中2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与富马酸的摩尔比为1:0.5。
使用Cu-Kα辐射，所述富马酸共晶晶型的X-射线粉末衍射图在2θ值为8.3°±0.2°、9.8°±0.2°、16.7°±0.2°具有特征峰。
在本发明优选的一个实施方案中，所述富马酸共晶晶型的X-射线粉末衍射图还在2θ值为15.5°±0.2°、16.4°±0.2°、23.4°±0.2°、23.7°±0.2°、24.2°±0.2°、27.1°±0.2°和28.3°±0.2°的一处或多处具有特征峰。
在本发明又一个优选的实施方案中，所述富马酸共晶晶型的X-射线粉末衍射图还在2θ值为15.5°±0.2°、16.4°±0.2°、23.4°±0.2°、23.7°±0.2°、24.2°±0.2°、27.1°±0.2°和28.3°±0.2°处具有特征峰。
非限制性地，所述富马酸共晶晶型的一个具体实例具有如图12所示的XRPD图谱。
在本发明又一个优选的实施方案中，所述富马酸共晶晶型的傅里叶红外光谱在波数为3350cm-1±2cm-1、3153cm-1±2cm-1、1681cm-1±2cm-1、1588cm-1±2cm-1、1395cm-1±2cm-1、1320cm-1±2cm-1、1149cm-1±2cm-1、971cm-1±2cm-1、870cm-1±2cm-1、835cm-1±2cm-1、747cm-1±2cm-1和634cm-1±2cm-1处具有特征峰。
本发明的另一个目的是提供富马酸共晶单晶及其制备方法。所述富马酸共晶晶型的单晶，属于三斜晶系，空间群P1，在296K条件下进行测量，具有以下的单晶晶胞参数：
Figure PCTCN2017077459-appb-000009
α＝99.9°±0.2°；β＝102.3°±0.2°；γ＝108.4°±0.2°。
优选地，该共晶单晶的晶胞参数为
Figure PCTCN2017077459-appb-000010
Figure PCTCN2017077459-appb-000011
α＝99.9°～100.0°；β＝102.3°～102.4°；γ＝108.38°～108.43°。更具体地，该共晶单晶的晶胞参数为
Figure PCTCN2017077459-appb-000012
Figure PCTCN2017077459-appb-000013
α＝99.93°～99.94°；β＝102.31°～102.32°；γ＝108.40°～108.41°。
在一个具体的实施方案中，晶胞参数为
Figure PCTCN2017077459-appb-000014
Figure PCTCN2017077459-appb-000015
α＝99.932(2)°；β＝102.311(3)°；γ＝108.401(3)°。
进一步地，在本发明的一个具体实施方案中，所述的富马酸共晶晶型的单晶具有以下的原子坐标。
Figure PCTCN2017077459-appb-000016
Figure PCTCN2017077459-appb-000017
在本发明的优选的一个实施方案中，制备得到所述富马酸共晶晶型的单晶。制备的具体操作例如：将富马酸共晶的甲醇溶液进行室温小孔挥发，得到单晶。所述“小孔挥发”是将装有溶液的容器在相应温度下通过直径为2毫米的单个小孔进行挥发结晶。
与现有技术的LY2157299一水合物相比，本发明的富马酸共晶晶型具有以下有益性质：
(1)由对比例1可知，已知的LY2157299一水合物在室温下的水中表观溶解度小于50μg/mL，而本发明富马酸共晶晶型在水中的表观溶解度为330μg/mL，具有更好的水中表观溶解度。
(2)由DSC和TGA图谱可知，已知的LY2157299一水合物受温度影响脱去水分子出现晶型转变，而本发明的富马酸共晶晶型在分解之前未出现转晶，故本 发明的富马酸共晶晶型具有更好的晶型稳定性。
(3)本发明的富马酸共晶晶型晶体形貌为规则块状晶体，与细针状LY2157299一水合物相比，具有更好的流动性和制剂可加工性。
(4)本发明的富马酸共晶晶型在25℃-60％相对湿度条件下放置6个月，晶型不变，稳定性好。
以上有益性质表明：与现有技术的LY2157299的一水合物相比，本发明的富马酸共晶晶型有多种优势性能，更适合作为药物制剂中活性成分的固体形态。现有技术的LY2157299的一水合物溶解度低，影响制剂的吸收、利用。而本发明的富马酸共晶晶型水中溶解度高，具有更高的溶出度和生物利用度。且本发明的富马酸共晶晶型稳定性好，能更好地保证药物活性成分自身和含有富马酸共晶晶型的制剂剂型在制造和存储等过程中质量、安全性和稳定性。
本发明提供富马酸共晶晶型的制备方法，包括下述方法中的任意一种：
(1)将溶剂加入到LY2157299一水合物和富马酸的混合物中，研磨至干，得到所述的富马酸共晶晶型；所述溶剂选自甲醇、乙腈或水；
优选地，所述混合物和溶剂的质量体积比为60mg:1mL～160mg:1mL；
优选地，所述LY2157299一水合物与富马酸的摩尔比为1:0.5～1:1.2，更优选为1:0.5～1:0.6；
优选地，所述研磨的温度为10～40℃，更优选为10～30℃。
(2)将LY2157299一水合物和富马酸的混合物在溶剂中形成混悬液，搅拌析晶，进而分离晶体、干燥，得到所述的富马酸共晶晶型；所述溶剂选自C1～C4醇、乙酸乙酯或丙酮；
优选地，所述溶剂为甲醇；
优选地，所述LY2157299一水合物和富马酸的摩尔比为1:0.5～1:1.2，更优选为1:1.0～1:1.2；
优选地，所述LY2157299一水合物与溶剂的质量体积比为50～100mg/mL；
优选地，所述搅拌析晶的温度为10～40℃，更优选为10～30℃；
优选地，所述搅拌析晶的时间为4～16小时。
本发明的共晶的各制备方法中：原料“LY2157299”可以为已公开的LY2157299化合物、其晶型或其无定型物，例如包括但不限于参照专利文献US7872020B2中制备方法得到的LY2157299一水合物。这些专利文献通过引用其全文的方式并入到本申请中。
本发明中使用的术语有：
所述“C1～C4醇”包括甲醇、乙醇、正丙醇、异丙醇、正丁醇、仲丁醇和叔丁醇。
所述“室温”，是指10～30℃。
所述“搅拌”可以采用本领域的常规方法，例如搅拌方式包括磁力搅拌、 机械搅拌，搅拌速度为50～1800转/分，优选300～900转/分。
所述“研磨”可以采用本领域的常规方法，即在研钵内对样品进行研磨
所述“分离”可以采用本领域的常规方法，例如离心或过滤。优选减压过滤，一般是在室温下以小于大气压的压力进行抽滤，优选压力小于0.09MPa。
所述“干燥”，可以采用本领域的常规技术完成，例如常温干燥、鼓风干燥或减压干燥。干燥仪器和方法不受限制，可以是通风橱、鼓风烘箱、喷雾干燥器、流化床干燥或真空烘箱；可以减压或常压，优选压力小于0.09MPa。干燥温度为10～40℃，干燥时间为10～72小时，优选为2～24小时，更优选为2～8小时。
本发明中所述的“晶型”是指化合物被所示X-射线粉末衍射图谱表征所证实的，在晶格内具有独特有序的分子排列或构型。本领域技术人员公知，其中的实验误差取决于仪器条件、样品准备和样品纯度。XRPD图谱中的峰的2θ角度通常会随着仪器和样品不同而略有不同。峰角度的差值根据不同仪器，不同样品等可能相差1°，0.8°，0.5°，0.3°，0.1°等，通常允许误差±0.2°。峰的相对强度可能随样品、样品制备和其他实验条件而变化，所以峰强度的顺序不能作为唯一或决定性因素。样品高度等实验因素的影响会造成峰角度整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，任何具有与本发明X射线粉末衍射图谱相同或相似特征峰的晶型均属于本发明的范畴，即使峰强度和相对强度有所不同。“单一晶型”是指经X-射线粉末衍射检测为单一晶型。
本发明所述共晶是纯的、单一的，基本没有混合任何其他晶型或非晶态。本发明中“基本没有”当用来指新晶型时，指这个新晶型占所存在的化合物的至少80％(重量)，更指至少90％(重量)，尤其指至少95％(重量)，特别是指至少99％(重量)。
根据本发明目的，本发明提供一种药物组合物，所述药物组合物在制备用于治疗或预防与TGF-β有关的疾病中的用途；所述与TGF-β有关的疾病包括癌症、癌前病变、肾病、纤维变性及眼部疾病等。所述药物组合物含有治疗和/或预防有效量的药物活性成分选自本发明的LY2157299共晶或LY2157299可药用盐，以及至少一种药学上可接受的载体或助剂，其中所述本发明的LY2157299共晶包括LY2157299与琥珀酸形成的共晶和LY2157299与富马酸形成的共晶。任选地，所述药物组合物还可以包含一种或多种其他的药物活性成分，例如其他TGF-β拮抗剂、抗增殖/抗肿瘤药物。
根据本发明，治疗人类患者的方法包括施用TGF-β拮抗剂。将TGF-β拮抗剂制备成可通过口服和直肠途径、局部、皮下、胃肠外途径如注射施用的药物制剂形式，包括片剂、粉剂、胶囊剂、锭剂、乳剂、霜剂、糖浆剂、舌下片、小药袋、扁囊剂、酏剂、凝胶剂、混悬液、注射溶液、气雾剂、软膏、栓剂以及综合以上多种形式的复合制剂形式。
本发明的LY2157299共晶和组合物可以以单剂量或分剂量的形式在以活性 成分0.5mg/kg至50mg/kg的给药范围内给患者服用。单剂量可含化合物活性成分约0.5mg至约1000mg。用于口服时，该组合物可以含有约0.5至约500mg活性成分，特别是以含0.5mg、1mg、5mg、10mg、15mg、20mg、25mg、50mg、75mg、80mg/100mg、120mg、150mg、175mg、200mg、500mg等活性成分的片剂或胶囊的形式提供，以0.5mg/kg至40mg/kg活性成分的日剂量给药。实际施用的化合物量应根据各种相关情况，包括治疗的病症严重程度、患者的年龄、身体状况、性别、所施用的化合物的活性和代谢情况、给药途径来确定，因此上述优选剂量范围无意义任何方式限制本发明的范围。
化合物可以以含有本文指定的至少一种化合物共晶，混合以可药用载体、赋形剂、佐剂制成药物组合物或用胶囊、小药袋、扁囊、纸或其他外壳或支架形式的可吸收载体或一次性容器如安瓿包附或包封。载体、赋形剂、佐剂可以是固体、半固体或液体材料。本发明的药物组合物中可使用的载体、赋形剂、佐剂的例如有淀粉、糖、糖浆、山梨醇、甘露醇、二醇、石蜡、高岭土、硅酸钙、二氧化硅、聚乙烯吡咯烷酮、磷酸钙、可可脂、酯、油、藻酸盐、胶、甲基纤维素、微晶纤维素、润滑剂、粘合剂、崩解剂等。
本发明优选的药物形式为片剂、粉剂、胶囊、注射剂(溶液)、霜剂、软膏和气雾剂。
附图说明
图1参照US7872020B2制备的LY2157299一水合物晶型的XRPD图谱
图2参照US7872020B2制备的LY2157299一水合物晶型的DSC图谱
图3参照US7872020B2制备的LY2157299一水合物晶型的TGA图谱
图4参照US7872020B2制备的LY2157299一水合物晶型的PLM图谱
图5本发明琥珀酸共晶晶型的XRPD图谱
图6本发明琥珀酸共晶晶型的DSC图谱
图7本发明琥珀酸共晶晶型的TGA图谱
图8本发明琥珀酸共晶晶型的单晶的PLM图谱
图9本发明琥珀酸共晶晶型的单晶分子结构示意图
图10本发明琥珀酸共晶晶型的IR图谱
图11本发明琥珀酸共晶晶型的实测(下)和单晶衍射模拟(上)的XRPD对比图谱
图12本发明富马酸共晶晶型的XRPD图谱
图13本发明富马酸共晶晶型的DSC图谱
图14本发明富马酸共晶晶型的TGA图谱
图15本发明富马酸共晶晶型的单晶的PLM图谱
图16本发明富马酸共晶晶型的单晶分子结构示意图
图17本发明富马酸共晶晶型的IR图谱
图18本发明富马酸共晶晶型的实测(下)和单晶衍射模拟(上)的XRPD对比图谱
具体实施方案
通过下述实施例将有助于进一步理解本发明，但是不用于限制本发明的内容。
检测仪器及方法：
X-射线粉末衍射(XRPD)：仪器为Bruker D8 Advance diffractometer。样品在室温下测试。检测条件如下，角度范围：3～40°2θ，步长：0.02°2θ，速度：0.2秒/步。
单晶衍射仪：仪器为Bruker SMART APEX II，检测器为4K CCD，检测条件为：环境温度296K，增强型Mo光源，波长数据分析软件是Bruker SHELXTL。
差热分析数据采自于TA Instruments Q200 MDSC。检测方法为：取1～10毫克的样品放置于密闭小孔铝坩埚内，以10℃/min的升温速度在40mL/min干燥N2的保护下将样品从室温升至300℃。
热重分析数据采自于TA Instruments Q500 TGA。检测方法为：取5～15mg的样品放置于白金坩埚内，采用分段高分辨检测的方式，以10℃/min的升温速度在40mL/min干燥N2的保护下将样品从室温升至350℃。
核磁氢谱数据(1HNMR)采自于BrukerAvance II DMX 400MHZ核磁共振波谱仪。称量1～5mg样品，用约0.5mL氘代试剂溶解到核磁样品管中进行检测。
偏振光显微镜(PLM)型号为XR-500E，目镜倍数10倍，物镜倍数10倍。取少量样品于载玻片上，滴1滴硅油，盖上盖玻片分散后进行观察。
红外光谱分析(IR)数据采自于Bruker Tensor 27，采用ATR设备，在600-4000cm-1范围内，采集红外吸收光谱。
实施例中所用的各种试剂如无特别说明均为市售购买。
实施例中如无特别说明均为室温操作。
制备例1 LY2157299一水合物晶型的制备
参照专利文献US7872020B2中实施例1的方法制备得到LY2157299一水合物。
1H-NMR(CDCl3):δ＝9.0ppm(d,4.4Hz,1H)；8.23-8.19ppm(m,2H)；8.315ppm(dd,1.9Hz,8.9Hz,1H)；7.455ppm(d,4.4Hz,1H)；7.364ppm(t,7.7Hz,1H)；7.086ppm(d,8.0Hz,1H)；6.969ppm(d,7.7Hz,1H)；6.022ppm(m,1H)；5.497ppm(m,1H)；4.419ppm(d,7.3Hz,2H)；2.999ppm(m,2H)；2.770ppm(p,7.2Hz,7.4Hz,2H)；2.306ppm(s,3H)；1.817ppm(m,2H)。
其XRPD图谱如图1所示，其峰列表与专利文献US7872020B2报道的一水合物晶型的峰列表一致；
其DSC图谱如图2所示：133℃开始脱水并转晶，转晶后熔点为247℃；
其TGA图谱如图3所示：80～120℃有台阶失重4.7％，约合一摩尔水，分解温度约为323℃；
其PLM图谱如图4所示，显示为针状细小晶体。
实施例1
取192mg LY2157299一水合物和29.3mg琥珀酸混合，加入2.4mL甲醇，40℃条件下研磨至干，得到190mg琥珀酸共晶，产率86％。
其XRPD图谱如图5所示，显示为结晶态物质；其XRPD衍射峰、晶面间距和衍射峰强度数据如表1所示。
其DSC图谱如图6所示，在100℃-130℃范围内有脱水吸热峰。
其TGA图谱如图7所示，脱水温度约为80℃。
其IR图谱如图10所示。
表1琥珀酸共晶的衍射峰角度、晶面间距和峰相对强度数据
Figure PCTCN2017077459-appb-000019
实施例2
取适量实施例1中的琥珀酸共晶于甲醇中形成溶液，室温小孔挥发，得到琥珀酸共晶晶型的单晶晶体。
其单晶晶胞参数如表2所示，原子坐标如表3。
表2琥珀酸共晶的单晶晶胞参数
Figure PCTCN2017077459-appb-000020
表2中，a、b、c表示晶胞轴长，α、β、γ表示二面角，Z表示每个晶胞内以LY2157299·H2O·0.5HOOC(CH2)2COOH为单位分子的数目，V表示晶胞体积，Dcalc表示晶胞密度。
单晶解析相关参数：残差因子R1＝0.1004，加权R值wR2＝0.1617，拟合优度GooF(S)＝1.023，S值接近1，说明单晶数据合理。
其单晶PLM图谱如图8所示，显示为大块状晶体。
其单晶晶胞分子结构如图9所示，显示LY2157299分子和水分子在晶胞内，琥珀酸分子处于晶胞的顶点上，共晶分子由一个LY2157299分子、一个水分子和半个琥珀酸分子组成。
图11所示的对照图是单晶模拟的XRPD图(上)和实测的XRPD图(下)，显示两者基本一致。
表3琥珀酸共晶的单晶原子坐标
Figure PCTCN2017077459-appb-000021
Figure PCTCN2017077459-appb-000022
实施例3
取45mg LY2157299一水合物和8.3mg琥珀酸混合，加入0.3mL甲醇，10℃研磨至干，得到46mg琥珀酸共晶晶型，产率89％。
实施例4
取30mg LY2157299一水合物和9.1mg琥珀酸混合，加入0.15mL乙腈，10℃条件下研磨至干，得到29mg琥珀酸共晶晶型，产率84％。
实施例5
取15mg LY2157299一水合物和5.5mg琥珀酸混合，加入0.15mL水，40℃条件下研磨至干，得到14mg琥珀酸共晶晶型，产率81％。
实施例6
取50mg LY2157299一水合物和18.3mg琥珀酸，加入0.5mL甲醇形成混悬液，30℃搅拌析晶，4小时后，过滤，室温干燥1小时，得47mg琥珀酸共晶晶型，产率82％。
实施例7
取30mg LY2157299一水合物和4.6mg琥珀酸，加入0.6mL有乙醇形成混悬液，10℃搅拌析晶，16小时后，过滤，室温干燥1小时，得25mg琥珀酸共晶晶型，产率72％。
实施例8
取20mg LY2157299一水合物和7.3mg琥珀酸，加入0.25mL异丙醇形成混悬液，10℃搅拌析晶，8小时后，过滤，室温干燥1小时，得18mg琥珀酸共晶晶型，产率78％。
实施例9
取50mg LY2157299一水合物和15.2mg琥珀酸，加入1mL正丁醇形成混悬液，20℃搅拌析晶，10小时后，过滤，室温干燥1小时，得44mg琥珀酸共晶晶型，产率76％。
实施例10
取50mg LY2157299一水合物和8mg琥珀酸，加入0.5mL乙酸乙酯形成混悬液，40℃搅拌析晶，4小时后，过滤，室温干燥1小时，得43mg琥珀酸共晶晶型，产率75％。
实施例11
取50mg LY2157299一水合物和11mg琥珀酸，加入0.63mL丙酮形成混悬液，40℃搅拌析晶，4小时后，过滤，室温干燥1小时，得41mg琥珀酸共晶晶型，产率71％。
实施例3～11制备的样品具有与实施例1样品相同或相似的XRPD图谱、DSC图谱(未示出)和TGA图谱(未示出)、IR图谱(未示出)。说明实施例3～11样品与实施例1样品是相同的共晶。
实施例12
取15mg LY2157299一水合物和2.2mg富马酸，加入0.25mL甲醇，10℃条件下研磨至干，得到14mg富马酸共晶，产率85％。
其XRPD图谱如图12所示，显示为结晶态物质；其XRPD衍射峰、晶面间距和衍射峰强度数据如表4所示。
其DSC图谱如图13所示，显示熔点约为211℃。
其TGA图谱如图14所示，显示为无水物。
其IR图谱如图17所示。
表4富马酸共晶的衍射峰角度、晶面间距和峰相对强度数据
Figure PCTCN2017077459-appb-000023
实施例13
取适量实施例12的富马酸共晶在甲醇中形成溶液，室温小孔挥发，得到富马酸共晶晶型的单晶。
其单晶晶胞参数如表5所示，原子坐标如表6。
表5富马酸共晶的单晶晶胞参数
Figure PCTCN2017077459-appb-000024
Figure PCTCN2017077459-appb-000025
表5中，a、b、c表示晶胞轴长，α、β、γ表示二面角，Z表示每个晶胞内以LY2157299·0.5HOOC(CH)2COOH为单位分子的数目，V表示晶胞体积，Dcalc表示晶胞密度。
单晶解析相关参数：残差因子R1＝0.1145，加权R值wR2＝0.1606，拟合优度GooF(S)＝1.008，S值接近1，说明单晶数据合理。
其单晶PLM图谱如图15所示，显示为大块状晶体。
其单晶晶胞图谱如图16所示，显示LY2157299分子在晶胞内，富马酸分子处于面上，共晶分子由一个LY2157299分子和半个富马酸分子组成。
图18所示的对照图是富马酸单晶模拟的XRPD图(上)和实测的XRPD图(下)，显示两者基本一致。
表6富马酸共晶的单晶原子坐标
Figure PCTCN2017077459-appb-000026
Figure PCTCN2017077459-appb-000027
实施例14
取72mg LY2157299一水合物和13.0mg富马酸，加入0.45mL甲醇，30℃研磨至干，得到69mg富马酸共晶晶型，产率87％。
实施例15
取30mg LY2157299一水合物和10.8mg富马酸，加入0.2mL乙腈，10℃研磨至干，得到26mg富马酸共晶晶型，产率79％。
实施例16
取15mg LY2157299一水合物和4.5mg富马酸，加入0.2mL水，40℃研磨至干，得到12mg富马酸共晶晶型，产率72％。
实施例17
取50mg LY2157299一水合物和7.6mg富马酸，加入0.5mL甲醇形成混悬液，30℃搅拌析晶，4小时后，过滤，室温干燥1小时，得48mg富马酸共晶晶型，产率83％。
实施例18
取50mg LY2157299一水合物和18.3mg富马酸，加入1mL有甲醇形成混悬液，10℃搅拌析晶，16小时后，过滤，室温干燥1小时，得51mg富马酸共晶晶型，产率89％。
实施例19
取30mg LY2157299一水合物和11mg富马酸，加入0.4mL异丙醇形成混悬液，20℃搅拌析晶，8小时后，过滤，室温干燥1小时，得27mg富马酸共晶晶型，产率78％。
实施例20
取20mg LY2157299一水合物和6.1mg富马酸，加入0.4mL正丁醇形成混悬液，40℃搅拌析晶，10小时后，过滤，室温干燥1小时，得16mg富马酸共晶晶型，产率69％。
实施例21
取50mg LY2157299一水合物和12.2mg富马酸，加入0.5mL乙酸乙酯形成混悬液，40℃搅拌析晶，4小时后，过滤，室温干燥1小时，得38mg富马酸共晶晶型，产率66％。
实施例22
取50mg LY2157299一水合物和10.7mg富马酸，加入0.63mL丙酮形成混 悬液，40℃搅拌析晶，4小时后，过滤，室温干燥1小时，得39mg富马酸共晶晶型，产率68％。
实施例14～22制备的样品具有与实施例12样品相同或相似的XRPD图谱(未示出)、DSC图谱(未示出)、TGA图谱(未示出)和IR图谱(未示出)。说明实施例14～22样品与实施例12样品是相同的共晶。
实施例23
Figure PCTCN2017077459-appb-000028
将琥珀酸共晶晶型或富马酸共晶晶型、淀粉、微晶纤维素、二氧化硅和滑石粉混合后填充到胶囊中。
实施例24
Figure PCTCN2017077459-appb-000029
将琥珀酸共晶晶型或富马酸共晶晶型、淀粉和微晶纤维素通过20目筛，并充分混合。将羟丙基甲基纤维素溶液与所得的粉末混合，然后通过16目筛，将得到的颗粒干燥并通过16目筛。然后，将预先通过30目筛的羧甲基淀粉钠、硬脂酸镁和滑石粉加入到颗粒中，混合后在制片机上压制成片剂，每片重150mg。
对比例1
取制备例1中的LY2157299一水合物、实施例1中的琥珀酸共晶晶型和实施例12中的富马酸共晶晶型进行水中表观溶解度测试，具体操作如下：
精确称量样品5mg置于200mL锥形瓶中，水浴温度为25±2℃，通过倍增法添加水，搅拌(约200转/分钟)，目测是否溶清，每次加水间隔3分钟，最大加水量为100mL。
结果见下表，显示本发明的琥珀酸共晶晶型和富马酸共晶晶型的水中溶解度均比现有技术的LY2157299一水合物好。
Figure PCTCN2017077459-appb-000030
以上所述，仅为本发明的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本领域的技术人员在本发明所揭露的技术范围内，可不经过创造性劳动想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应该以权利要求书所限定的保护范围为准。

Claims (21)

  1. 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与琥珀酸的共晶。
  2. 根据权利要求1所述的共晶，其特征在于，其中2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸的摩尔比为1：0.5。
  3. 根据权利要求2所述的共晶，其特征在于，该共晶含1摩尔的水。
  4. 根据权利要求1-3中任一项所述的共晶，其特征在于，所述共晶的晶型使用Cu-Kα辐射，其X-射线粉末衍射图在2θ值为10.8°±0.2°、11.6°±0.2°、15.5°±0.2°和20.2°±0.2°处具有特征峰。
  5. 根据权利要求4所述的共晶，其特征在于，所述共晶的晶型使用Cu-Kα辐射，其X-射线粉末衍射图还在2θ值为12.3°±0.2°、16.8°±0.2°、18.0°±0.2°、21.3°±0.2°、21.7°±0.2°、22.0°±0.2°、24.6°±0.2°和25.2°±0.2°的一处或多处具有特征峰。
  6. 根据权利要求5所述的共晶，其特征在于，所述共晶晶型的X-射线粉末衍射图还在2θ值为12.3°±0.2°、16.8°±0.2°、18.0°±0.2°、21.3°±0.2°、21.7°±0.2°、22.0°±0.2°、24.6°±0.2°和25.2°±0.2°处具有特征峰。
  7. 根据权利要求4～6中任一项所述的共晶，其特征在于，所述共晶的傅里叶红外光谱在波数为3473cm-1±2cm-1、3141cm-1±2cm-1、1693cm-1±2cm-1、1580cm-1±2cm-1、1429cm-1±2cm-1、1322cm-1±2cm-1、1189cm-1±2cm-1、864cm-1±2cm-1、831cm-1±2cm-1、806cm-1±2cm-1和609cm-1±2cm-1处具有特征峰。
  8. 一种2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与琥珀酸的共晶单晶，其特征在于，该共晶为权利要求4～7中任一项所述的晶型，所述共晶单晶属于三斜晶系，空间群P1，具有下列的单晶晶胞参数：
    Figure PCTCN2017077459-appb-100001
    α＝87.3°±0.2°；β＝78.1°±0.2°；γ＝89.2°±0.2°。
  9. 权利要求4～7中任一项所述的共晶的制备方法，所述制备方法包括下述方法中的任意一种：
    (1)将溶剂加入到LY2157299一水合物和琥珀酸的混合物中，研磨至干，得到所述的共晶；所述溶剂选自甲醇、乙腈或水；
    优选地，所述LY2157299一水合物与琥珀酸的摩尔比为1:0.5～1:1.2，更优选为1:0.5～1:0.6；
    优选地，所述LY2157299一水合物与溶剂的质量体积比为80mg:1mL～200mg:1mL，更优选为80mg:1mL～150mg:1mL；
    优选地，所述研磨的温度为10～40℃，更优选为10～30℃；
    (2)将LY2157299一水合物和琥珀酸的混合物在溶剂中形成混悬液，搅拌 析晶，进而分离晶体、干燥，得到所述的共晶；所述溶剂选自C1～C4醇、乙酸乙酯或丙酮；
    优选地，所述溶剂为甲醇；
    优选地，所述LY2157299一水合物和琥珀酸的摩尔比为1:0.5～1:1.2，更优选为1:1.0～1:1.2；
    优选地，所述LY2157299一水合物与溶剂的质量体积比为50～100mg/mL；
    优选地，所述搅拌析晶的温度为10～40℃，更优选为10～30℃；
    优选地，所述搅拌析晶的时间为4～16小时。
  10. 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与富马酸的共晶。
  11. 根据权利要求10所述的共晶，其特征在于，其中2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和富马酸的摩尔比为1：0.5。
  12. 根据权利要求10～11中任一项所述的共晶，其特征在于，所述共晶的晶型使用Cu-Kα辐射，其X-射线粉末衍射图在2θ值为8.3°±0.2°、9.8°±0.2°、16.7°±0.2°处处具有特征峰。
  13. 根据权利要求12所述的共晶，其特征在于，所述共晶晶型的X-射线粉末衍射图还在2θ值为15.5°±0.2°、16.4°±0.2°、23.4°±0.2°、23.7°±0.2°、24.2°±0.2°、27.1°±0.2°和28.3°±0.2°的一处或多处具有特征峰：。
  14. 根据权利要求13所述的共晶，其特征在于，所述共晶晶型的X-射线粉末衍射图还在2θ值为15.5°±0.2°、16.4°±0.2°、23.4°±0.2°、23.7°±0.2°、24.2°±0.2°、27.1°±0.2°和28.3°±0.2°处具有特征峰。
  15. 根据权利要求12～14中任一项所述的共晶，其特征在于，所述共晶的傅里叶红外光谱在波数为3350cm-1±2cm-1、3153cm-1±2cm-1、1681cm-1±2cm-1、1588cm-1±2cm-1、1395cm-1±2cm-1、1320cm-1±2cm-1、1149cm-1±2cm-1、971cm-1±2cm-1、870cm-1±2cm-1、835cm-1±2cm-1、747cm-1±2cm-1和634cm-1±2cm-1处具有特征峰。
  16. 一种2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑与富马酸的共晶单晶，其特征在于，该共晶为权利要求12～15中任一项所述的晶型，所述共晶单晶为三斜晶系，空间群P1，具有下列的单位晶胞参数：
    Figure PCTCN2017077459-appb-100002
    α＝99.9°±0.2°；β＝102.3°±0.2°；γ＝108.4°±0.2°。
  17. 权利要求12～15中任一项所述的共晶的制备方法，所述制备方法包括下述方法中的任意一种：
    (1)将溶剂加入到LY2157299一水合物和富马酸的混合物中，研磨至干，得到所述的共晶；所述溶剂选自甲醇、乙腈或水；
    优选地，所述混合物和溶剂的质量体积比为60mg:1mL～160mg:1mL；
    优选地，所述LY2157299一水合物与富马酸的摩尔比为1:0.5～1:1.2，更优选为1:0.5～1:0.6；
    优选地，所述研磨的温度为10～40℃，更优选为10～30℃；
    (2)将LY2157299一水合物和富马酸的混合物在溶剂中形成混悬液，搅拌析晶，进而分离晶体、干燥，得到所述的共晶；所述溶剂选自C1～C4醇、乙酸乙酯或丙酮；
    优选地，所述溶剂为甲醇；
    优选地，所述LY2157299一水合物和富马酸的摩尔比为1:0.5～1:1.2，更优选为1:1.0～1:1.2；
    优选地，所述LY2157299一水合物与溶剂的质量体积比为50～100mg/mL；
    优选地，所述搅拌析晶的温度为10～40℃，更优选为10～30℃；
    优选地，所述搅拌析晶的时间为4～16小时。
  18. 一种药物组合物，其包含治疗有效量的权利要求1～8中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸形成的共晶，权利要求10～15中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和富马酸形成的共晶，以及至少一种药学上可接受的载体或助剂。
  19. 根据权利要求18所述的药物组合物，其特征在于，所述药物组合物为选自适合口服、直肠、局部、皮下或胃肠外给药如注射的制剂形式，包括片剂、粉剂、胶囊剂、锭剂、乳剂、霜剂、糖浆剂、舌下片、小药袋、扁囊剂、酏剂、凝胶剂、混悬液、注射溶液、气雾剂、软膏、栓剂以及综合以上多种形式的复合制剂形式。
  20. 权利要求1～8中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸形成的共晶，权利要求10～15中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和富马酸形成的共晶在制备用于治疗或预防与TGF-β有关的疾病中的用途；所述与TGF-β有关的疾病包括癌症、癌前病变、肾病、纤维变性及眼部疾病等。
  21. 一种治疗和/或预防与TGF-β有关的疾病的方法，所述方法包括给予需要的患者治疗和/或预防有效量的一种或多种选自权利要求1～8中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和琥珀酸形成的共晶，权利要求10～15中任一项所述的2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑和富马酸形成的共晶或权利要求18～19中任一项所述的药物组合物；所述与TGF-β有关的疾病包括癌症、癌前病变、肾病、肺纤维变性及眼部疾病等。
PCT/CN2017/077459 2017-03-21 2017-03-21 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 WO2018170724A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201780090404.6A CN110582279B (zh) 2017-03-21 2017-03-21 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
US16/496,023 US10995083B2 (en) 2017-03-21 2017-03-21 Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition
PCT/CN2017/077459 WO2018170724A1 (zh) 2017-03-21 2017-03-21 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077459 WO2018170724A1 (zh) 2017-03-21 2017-03-21 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物

Publications (1)

Publication Number Publication Date
WO2018170724A1 true WO2018170724A1 (zh) 2018-09-27

Family

ID=63584006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/077459 WO2018170724A1 (zh) 2017-03-21 2017-03-21 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物

Country Status (3)

Country Link
US (1) US10995083B2 (zh)
CN (1) CN110582279B (zh)
WO (1) WO2018170724A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995083B2 (en) 2017-03-21 2021-05-04 Hangzhou Solipharma Co., Ltd. Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072517A1 (en) * 2012-11-12 2014-05-15 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
WO2016123573A1 (en) * 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2007018818A1 (en) 2005-07-22 2007-02-15 Eli Lilly And Company A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
CN102424681B (zh) * 2011-10-24 2014-10-15 华东师范大学 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
US10995083B2 (en) 2017-03-21 2021-05-04 Hangzhou Solipharma Co., Ltd. Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072517A1 (en) * 2012-11-12 2014-05-15 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
WO2016123573A1 (en) * 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995083B2 (en) 2017-03-21 2021-05-04 Hangzhou Solipharma Co., Ltd. Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition

Also Published As

Publication number Publication date
CN110582279A (zh) 2019-12-17
US20200017470A1 (en) 2020-01-16
CN110582279B (zh) 2023-07-14
US10995083B2 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
JP5086267B2 (ja) 臭化チオトロピウムの新規な形態およびそれを製造する方法
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2018049632A1 (zh) 奥扎莫德的晶型、其制备方法及药物组合物
WO2016054959A1 (zh) 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
WO2019062854A1 (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
RU2548044C2 (ru) Новые кристаллические формы n-[-2[[(2,3-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азетидин-сульфонамида
JP2023062091A (ja) Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
CN110582497B (zh) Galunisertib的晶型及其制备方法和药物组合物
TW201617347A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
US11236073B2 (en) ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof
WO2019183916A1 (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
WO2019200502A1 (zh) 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
CN108299412B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US7777049B2 (en) Crystalline forms of Rizatriptan benzoate
EP2729460B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
CN108137578B (zh) Abt-199加成盐及其晶型、其制备方法和药物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17902171

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.11.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17902171

Country of ref document: EP

Kind code of ref document: A1